Intervention with mesenchymal stem cells (MSCs) represents a promising therapeutic tool in treatment-refractory autoimmune diseases. A new report by Schurgers and colleagues in a previous issue of Arthritis Research & Therapy sheds novel mechanistic insight into the pathways employed by MSCs to suppress T-cell proliferation in vitro, but, at the same time, indicates that MSCs do not influence T-cell reactivity and the disease course in an in vivo arthritis model. Such discrepancies between the in vitro and in vivo effects of potent cellular immune modulators should spark further research and should be interpreted as a sign of caution for the in vitro design of MSC-derived interventions in the setting of human autoimmune diseases. © 2010 BioMed Central Ltd.
CITATION STYLE
Scherer, H. U., van Pel, M., & Toes, R. E. M. (2010, June 18). Mesenchymal stem cells in autoimmune diseases: Hype or hope? Arthritis Research and Therapy. https://doi.org/10.1186/ar3036
Mendeley helps you to discover research relevant for your work.